Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse

Onesti, Concetta Elisa; Josse, Claire; Boulet, Delphine; Thiry, Jérôme; Beaumecker, Barbara; Jerusalem, Guy

doi:10.1080/2162402x.2020.1761176

Cited by 25 publications

(28 citation statements)

References 44 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence indicates the presence of eosinophils in the TME of several human hematological and solid tumors, including BC, even if the mechanisms responsible of the eosinophil infiltration into the tumors are not completely known (92)(93)(94). However, some data show that the high-mobility group box 1 protein (HMGB1), IL-1a, and IL-33 potentially trigger eosinophil recruitment (95).…”

Section: Eosinophilsmentioning

confidence: 99%

“…reported that BC patients with eosinophil counts of less than 55/mm 3 had significantly higher risk of recurrent disease than patients who had normal or high levels of eosinophils ( 102 ). Moreover, a study on a cohort of 930 BC patients reported a benefit for relative eosinophil count (REC)-high vs REC-low in BC-specific survival and in time to treatment failure ( 93 ).…”

Section: Major Players In Bc Immune Microenvironmentmentioning

confidence: 99%

See 1 more Smart Citation

The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy

et al. 2021

View full text Add to dashboard Cite

Breast cancer progression is a complex process controlled by genetic and epigenetic factors that coordinate the crosstalk between tumor cells and the components of tumor microenvironment (TME). Among those, the immune cells play a dual role during cancer onset and progression, as they can protect from tumor progression by killing immunogenic neoplastic cells, but in the meanwhile can also shape tumor immunogenicity, contributing to tumor escape. The complex interplay between cancer and the immune TME influences the outcome of immunotherapy and of many other anti-cancer therapies. Herein, we present an updated view of the pro- and anti-tumor activities of the main immune cell populations present in breast TME, such as T and NK cells, myeloid cells, innate lymphoid cells, mast cells and eosinophils, and of the underlying cytokine-, cell–cell contact- and microvesicle-based mechanisms. Moreover, current and novel therapeutic options that can revert the immunosuppressive activity of breast TME will be discussed. To this end, clinical trials assessing the efficacy of CAR-T and CAR-NK cells, cancer vaccination, immunogenic cell death-inducing chemotherapy, DNA methyl transferase and histone deacetylase inhibitors, cytokines or their inhibitors and other immunotherapies in breast cancer patients will be reviewed. The knowledge of the complex interplay that elapses between tumor and immune cells, and of the experimental therapies targeting it, would help to develop new combination treatments able to overcome tumor immune evasion mechanisms and optimize clinical benefit of current immunotherapies.

show abstract

Section: Eosinophilsmentioning

confidence: 99%

Section: Major Players In Bc Immune Microenvironmentmentioning

confidence: 99%

The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…We observed a positive association between baseline and post-surgery relative eosinophil count (REC) with pCR and survival [ 56 ]. We also studied the prognostic value of circulating eosinophils in a larger cohort of 930 early-stage breast cancer patients, observing a positive association between higher REC and better outcome, independent of the subtype [ 73 ]. In the subgroup analysis, a better prognosis for almost all subgroups was observed, in particular for patients not receiving chemotherapy or anti-HER2 treatment [ 73 ].…”

Section: Eosinophils and Breast Cancermentioning

confidence: 99%

Immunity and Breast Cancer: Focus on Eosinophils

Poncin¹,

Onesti

Josse

et al. 2021

Biomedicines

Self Cite

View full text Add to dashboard Cite

The role of eosinophils, a cell type involved in the immune response to parasitic infections and allergies, has been investigated in different cancer types, in both tumor tissue and at the circulating level. Most studies showed a role mainly in conjunction with immunotherapy in melanomas and lung tumors, while few data are available in breast cancer. In this review, we summarize literature data on breast cancer, showing a prognostic role of circulating eosinophil counts as well as of the presence of tumor tissue infiltration by eosinophils. In particular, some studies showed an association between a higher circulating eosinophil count and a good prognosis, as well as an association with response to neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive and in triple negative breast cancer. Several mechanistic studies have also been conducted in in vivo models, but the exact mechanism by which eosinophils act in the presence of breast cancer is still unknown. Further studies on this subject are desirable, in order to understand their role at the cellular level, identify related biomarkers and/or possibly search for new therapeutic targets.

show abstract

“…Similar results could be found in recent studies. Low blood eosinophilic relative count was associated with a worse prognosis in 930 breast cancer patients [ 37 ]. Moreover, there was a positive correlation between eosinophilic relative counts and both pathological complete remission and survival rate in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Overexpression of MAL2 Correlates with Immune Infiltration and Poor Prognosis in Breast Cancer

Zhong

Zhuang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Myelin and lymphocyte, T cell differentiation protein 2 (MAL2) is highly expressed in various cancers and associated with the development and prognosis of cancer. However, the relationship between MAL2 and breast cancer requires further investigation. This study aimed to explore the prognostic significance of MAL2 in breast cancer. Methods. MAL2 expression was initially assessed using the Oncomine database and The Cancer Genome Atlas (TCGA) database and verified by quantitative real-time polymerase chain reaction (RT-qPCR). The chi-square test or Fisher’s exact test was used to explore the association between clinical characteristics and MAL2 expression. The prognostic value of MAL2 in breast cancer was assessed by the Kaplan–Meier method and Cox regression analysis. Gene set enrichment analysis (GSEA) was performed to identify the biological pathways correlated with MAL2 expression in breast cancer. Besides, a single-sample GSEA (ssGSEA) was used to assess the relationship between the level of immune infiltration and MAL2 in breast cancer. Results. Both bioinformatics and RT-qPCR results showed that MAL2 was expressed at high levels in breast cancer tissues compared with the adjacent tissues. The chi-square test or Fisher’s exact test indicated that MAL2 expression was related to stage, M classification, and vital status. Kaplan–Meier curves implicated that high MAL2 expression was significantly associated with the poor prognosis. Cox regression models showed that high MAL2 expression could be an independent risk factor for breast cancer. GSEA showed that 14 signaling pathways were enriched in the high-MAL2-expression group. Besides, the MAL2 expression level negatively correlated with infiltrating levels of eosinophils and plasmacytoid dendritic cells in breast cancer. Conclusion. Overexpression of MAL2 correlates with poor prognosis and lower immune infiltrating levels of eosinophils and plasmacytoid dendritic cells in breast cancer and may become a biomarker for breast cancer prognosis.

show abstract

Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse

Cited by 25 publications

References 44 publications

The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy

The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy

Immunity and Breast Cancer: Focus on Eosinophils

Overexpression of MAL2 Correlates with Immune Infiltration and Poor Prognosis in Breast Cancer

Contact Info

Product

Resources

About